Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin

Diagnostic Pathology

Zhe Liu¹  Wen-zhi Zhang¹  Jia-hong Dong¹  Xiang-qian Zhao¹ 

[1] Hospital & Institute of Hepatobiliary Surgery, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China

关键词: Cytokeratin 7;    Cytokeratin 20;    classification;    immunohistochemistry;    survival analysis;    osteopontin;    ampullary cancer;   

Others  :  808226
DOI  :  10.1186/1746-1596-6-98

 received in 2011-08-30, accepted in 2011-10-13,  发布年份 2011

【 摘 要 】

Background

Ampullary cancer (AC) was classified as pancreatobiliary, intestinal, or other subtype based on the expression of cytokeratin 7 (CK7) and cytokeratin 20 (CK20). We aimed to explore the association of AC subtype with patient prognosis.

Methods

The relationship of AC subtype and expression of Osteopontin (OPN) with the prognosis of 120 AC patients after pancreaticoduodenectomy was investigated.

Results

The patients had pancreatobiliary (CK7⁺/CK20^-, n = 24, 20%), intestinal (CK7^-/CK20⁺, n = 29, 24.2%) or other (CK7⁺/CK20⁺ or CK7^-/CK20^-, n = 67, 55.8%) subtypes of AC, and their median survival times were 23 ± 4.2, 38 ± 2.8 and 64 ± 16.8 months, respectively. The survival times of 64 OPN^- patients (53.3%) and 56 OPN⁺ patients (46.7%) were 69 ± 18.4 and 36 ± 1.3 months, respectively. There was no significant effect of AC subtype on survival of OPN^- patients. For OPN⁺ patients, those with pancreatobiliary AC had a shorter survival time (22 ± 6.6 months) than those with intestinal AC (37 ± 1.4 months, p = 0.041), and other AC subtype (36 ± 0.9 months, p = 0.010); intestinal and other AC subtypes had similar survival times.

Conclusions

The prognosis of AC patients can be estimated based on immunohistochemical classification and OPN status.

【 授权许可】

   
2011 Zhao et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Howe JR, Klimstra DS, Moccia RD, Conlon KC, Brennan MF: Factors predictive of survival in ampullary carcinoma. Ann Surg 1998, 228:87-94.
• [2]Kimura W, Futakawa N, Yamagata S, Wada Y, Kuroda A, Muto T, Esaki Y: Different clinicopathologic findings in two histologic types of carcinoma of papilla of Vater. Jpn J Cancer Res 1994, 85:161-166.
• [3]Zhou H, Schaefer N, Wolff M, Fischer HP: Carcinoma of the Ampulla of Vater: Comparative Histologic/Immunohistochemical Classification and Follow-up. Am J Surg Pathol 2004, 28:875-882.
• [4]de Paiva Haddad LB, Patzina RA, Penteado S, Montagnini AL, da Cunha JE, Machado MC, Jukemura J: Lymph node involvement and not the histophatologic subtype is correlated with outcome after resection of adenocarcinoma of the ampulla of vater. J Gastrointest Surg 2010, 14:719-728.
• [5]Le Pessot F, Ranty ML, Hellot MF, Lemoine F, Teniere P, Testart J, Metayer J: Cytokeratins 7 and 20 immunohistochemistry in ampullary carcinomas. Ann Pathol 2004, 24:312-318.
• [6]Westgaard A, Schjolberg AR, Cvancarova M, Eide TJ, Clausen OP, Gladhaug IP: Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours. Histopathology 2009, 54:337-347.
• [7]Santini D, Baldi A, Vincenzi B, Mellone P, Campioni M, Antinori A, Borzomati D, Coppola R, Magistrelli P, Tonini G: Mucin 2 (MUC2) and mucin 5 (MUC5) expression is not associated with prognosis in patients with radically resected ampullary carcinoma. J Clin Pathol 2007, 60:1069-1070.
• [8]Moriya T, Kimura W, Hirai I, Takasu N, Mizutani M: Expression of MUC1 and MUC2 in Ampullary Cancer. Int J Surg Pathol 2011, 19:441-447.
• [9]Ehehalt F, Rummele P, Kersting S, Lang-Schwarz C, Ruckert F, Hartmann A, Dietmaier W, Terracciano L, Aust DE, Jahnke B, Saeger HD, Pilarsky C, Grutzmann R: Hepatocyte Nuclear Factor (HNF) 4alpha Expression Distinguishes Ampullary Cancer Subtypes and Prognosis After Resection. Ann Surg 2011, 254:302-310.
• [10]Fischer HP, Zhou H: Pathogenesis of carcinoma of the papilla of Vater. J Hepatobiliary Pancreat Surg 2004, 11:301-309.
• [11]Kawabata Y, Tanaka T, Nishisaka T, Inao T, Nishi T, Yano S: Cytokeratin 20 (CK20) and apomucin 1 (MUC1) expression in ampullary carcinoma: Correlation with tumor progression and prognosis. Diagn Pathol 2010, 5:75.
• [12]Goparaju CM, Pass HI, Blasberg JD, Hirsch N, Donington JS: Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. J Thorac Oncol 2010, 5:1516-1523.
• [13]Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ: Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004, 10:184-190.
• [14]Lorenzen JM, Nickel N, Kramer R, Golpon H, Westerkamp V, Olsson KM, Haller H, Hoeper MM: Osteopontin in patients with idiopathic pulmonary hypertension. Chest 2011, 139:1010-1017.
• [15]Isa S, Kawaguchi T, Teramukai S, Minato K, Ohsaki Y, Shibata K, Yonei T, Hayashibara K, Fukushima M, Kawahara M, Furuse K, Mack PC: Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. J Thorac Oncol 2009, 4:1104-1110.
• [16]Li Y, Li L, Wang JT, Kan X, Lu JG: Elevated content of osteopontin in plasma and tumor tissues of patients with laryngeal and hypopharyngeal carcinoma associated with metastasis and prognosis. Med Oncol 2011, 28:1-6.
• [17]Sieghart W, Wang X, Schmid K, Pinter M, Konig F, Bodingbauer M, Wrba F, Rasoul-Rockenschaub S, Peck-Radosavljevic M: Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. J Hepatol 2011, 54:89-97.
• [18]Likui W, Hong W, Shuwen Z: Clinical significance of the upregulated osteopontin mRNA expression in human colorectal cancer. J Gastrointest Surg 2010, 14:74-81.
• [19]Weber GF, Lett GS, Haubein NC: Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 2010, 103:861-869.
• [20]Ke HL, Chang LL, Yang SF, Lin HH, Li CC, Wu DC, Wu WJ: Osteopontin overexpression predicts poor prognosis of upper urinary tract urothelial carcinoma. Urol Oncol 2009.
• [21]Powell JA, Thomas D, Barry EF, Kok CH, McClure BJ, Tsykin A, To LB, Brown A, Lewis ID, Herbert K, Goodall GJ, Speed TP, Asou N, Jacob B, Osato M, Haylock DN, Nilsson SK, D'Andrea RJ, Lopez AF, Guthridge MA: Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. Blood 2009, 114:4859-4870.
• [22]Chien CY, Su CY, Chuang HC, Fang FM, Huang HY, Chen CH, Chen CM, Huang CC: Comprehensive study on the prognostic role of osteopontin expression in oral squamous cell carcinoma. Oral Oncol 2009, 45:798-802.
• [23]Cho H, Kang ES, Kim YT, Kim JH: Diagnostic and prognostic impact of osteopontin expression in endometrial cancer. Cancer Invest 2009, 27:313-323.
• [24]Lorenzen JM, Hafer C, Faulhaber-Walter R, Kumpers P, Kielstein JT, Haller H, Fliser D: Osteopontin predicts survival in critically ill patients with acute kidney injury. Nephrol Dial Transplant 2011, 26:531-537.
• [25]Van Heek NT, Maitra A, Koopmann J, Fedarko N, Jain A, Rahman A, Iacobuzio-Donahue CA, Adsay V, Ashfaq R, Yeo CJ, Cameron JL, Offerhaus JA, Hruban RH, Berg KD, Goggins M: Gene expression profiling identifies markers of ampullary adenocarcinoma. Cancer Biol Ther 2004, 3:651-656.
• [26]Bloomston M, Ellison EC, Muscarella P, Al-Saif O, Martin EW, Melvin WS, Frankel WL: Stromal osteonectin overexpression is associated with poor outcome in patients with ampullary cancer. Ann Surg Oncol 2007, 14:211-217.
• [27]Hsu HP, Shan YS, Lai MD, Lin PW: Osteopontin-positive infiltrating tumor-associated macrophages in bulky ampullary cancer predict survival. Cancer Biol Ther 2010, 10:144-154.
• [28]Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M: AJCC Cancer Staging Manual (6th Edition). 6th edition. New York, NY: Springer; 2002.
• [29]Goldstein NS, Bassi D: Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of vater adenocarcinomas. Percentage of positivity and distribution is affected by the cut-point threshold. Am J Clin Pathol 2001, 115:695-702.
• [30]Matsuzaki H, Shima K, Muramatsu T, Ro Y, Hashimoto S, Shibahara T, Shimono M: Osteopontin as biomarker in early invasion by squamous cell carcinoma in tongue. J Oral Pathol Med 2007, 36:30-34.
• [31]Hsu KH, Tsai HW, Lin PW, Hsu YS, Shan YS, Lu PJ: Osteopontin expression is an independent adverse prognostic factor in resectable gastrointestinal stromal tumor and its interaction with CD44 promotes tumor proliferation. Ann Surg Oncol 2010, 17:3043-3052.
• [32]Yang GH, Fan J, Xu Y, Qiu SJ, Yang XR, Shi GM, Wu B, Dai Z, Liu YK, Tang ZY, Zhou J: Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection. Oncologist 2008, 13:1155-1165.
• [33]Zhang X, Tsukamoto T, Mizoshita T, Ban H, Suzuki H, Toyoda T, Tatematsu M: Expression of osteopontin and CDX2: indications of phenotypes and prognosis in advanced gastric cancer. Oncol Rep 2009, 21:609-613.